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doi:10.1016/j.ijsu.2010.02.0071. Introduction six domains. Reporting was generally poor; between one and 14Systematic reviews and meta-analyses have become
increasingly important in health care. Clinicians read them to
keep up to date with their ﬁeld,1,2 and they are often used as
a starting point for developing clinical practice guidelines.
Granting agencies may require a systematic review to ensure
there is justiﬁcation for further research,3 and some health care
journals are moving in this direction.4 As with all research, the
value of a systematic review depends on what was done, what
was found, and the clarity of reporting. As with other publica-
tions, the reporting quality of systematic reviews varies, limiting
readers’ ability to assess the strengths and weaknesses of those
reviews.
Several early studies evaluated the quality of review reports. In
1987, Mulrow examined 50 review articles published in four
leading medical journals in 1985 and 1986 and found that none
met all eight explicit scientiﬁc criteria, such as a quality assess-
ment of included studies.5 In 1987, Sacks et al.6 evaluated the
adequacy of reporting of 83 meta-analyses on 23 characteristics ins for systematic reviews and
a-analyses
, Ottawa Hospital Research
the Acknowledgments.
ciates Ltd. Published by Elsevier Ltcharacteristics were adequately reported (mean¼ 7.7; standard
deviation¼ 2.7). A 1996 update of this study found little
improvement.7
In 1996, to address the suboptimal reporting of meta-analyses,
an international group developed a guidance called the QUOROM
Statement (quality of reporting of meta-analyses), which focused
on the reporting of meta-analyses of randomized controlled trials.8
In this article, we summarize a revision of these guidelines,
renamed PRISMA (preferred reporting items for systematic reviews
and meta-analyses), which have been updated to address several
conceptual and practical advances in the science of systematic
reviews (Box 1).2. Terminology
The terminology used to describe a systematic review andmeta-
analysis has evolved over time. One reason for changing the name
from QUOROM to PRISMA was the desire to encompass both
systematic reviews and meta-analyses. We have adopted the deﬁ-
nitions used by the Cochrane Collaboration.9 A systematic review is
a review of a clearly formulated question that uses systematic and
explicit methods to identify, select, and critically appraise relevant
research, and to collect and analyze data from the studies that are
included in the review. Statistical methods (meta-analysis) may or
may not be used to analyze and summarize the results of the
included studies. Meta-analysis refers to the use of statisticald. All rights reserved.
Box 1. Conceptual issues in the evolution from QUOROM to
PRISMA
Completing a systematic review is an iterative process
The conduct of a systematic review depends heavily on
the scope and quality of included studies: thus systematic
reviewers may need to modify their original review
protocol during its conduct. Any systematic review
reporting guideline should recommend that such
changes can be reported and explained without sug-
gesting that they are inappropriate. The PRISMA State-
ment (Items 5, 11, 16, and 23) acknowledges this iterative
process. Aside from Cochrane reviews, all of which
should have a protocol, only about 10% of systematic
reviewers report working from a protocol.22 Without
a protocol that is publicly accessible, it is difficult to judge
between appropriate and inappropriate modifications.
Conduct and reporting research are distinct concepts
This distinction is, however, less straightforward for
systematic reviews than for assessments of the report-
ing of an individual study, because the reporting and
conduct of systematic reviews are, by nature, closely
intertwined. For example, the failure of a systematic
review to report the assessment of the risk of bias in
included studies may be seen as a marker of poor
conduct, given the importance of this activity in the
systematic review process.37
Study-level versus outcome-level assessment of risk of bias
For studies included in a systematic review, a thorough
assessment of the risk of bias requires both a “study-
level” assessment (e.g., adequacy of allocation conceal-
ment) and, for some features, a newer approach called
“outcome-level” assessment. An outcome-level assess-
ment involves evaluating the reliability and validity of the
data for each important outcome by determining the
methods used to assess them in each individual study.38
The quality of evidencemay differ across outcomes, even
within a study, such as between a primary efficacy
outcome, which is likely to be very carefully and
systematically measured, and the assessment of serious
harms,39 which may rely on spontaneous reports by
investigators. This information should be reported to
allow an explicit assessment of the extent to which an
estimate of effect is correct.38
Importance of reporting biases
Different types of reporting biases may hamper the
conduct and interpretation of systematic reviews. Selec-
tive reportingof complete studies (e.g., publication bias)28
as well as the more recently empirically demonstrated
“outcome reporting bias” within individual studies40,41
should be considered by authors when conducting
a systematic review and reporting its results. Though the
implications of these biases on the conduct and reporting
of systematic reviews themselves are unclear, some
previous research has identified that selective outcome
reporting may occur also in the context of systematic
reviews.42
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included studies.
3. Developing the PRISMA statement
A three-day meeting was held in Ottawa, Canada, in June 2005
with 29 participants, including review authors, methodologists,clinicians, medical editors, and a consumer. The objective of the
Ottawa meeting was to revise and expand the QUOROM checklist
and ﬂow diagram, as needed.
The executive committee completed the following tasks, prior to
themeeting: a systematic reviewof studies examining the quality of
reporting of systematic reviews, and a comprehensive literature
search to identify methodological and other articles that might
inform the meeting, especially in relation to modifying checklist
items. An international survey of review authors, consumers, and
groups commissioning or using systematic reviews and meta-
analyses was completed, including the International Network of
Agencies for Health Technology Assessment (INAHTA) and the
Guidelines International Network (GIN). The survey aimed to
ascertain views of QUOROM, including the merits of the existing
checklist items. The results of these activitieswere presented during
the meeting and are summarized on the PRISMAWeb site (http://
www.prisma-statement.org/).
Only items deemed essential were retained or added to the
checklist. Some additional items are nevertheless desirable, and
review authors should include these, if relevant.10 For example, it is
useful to indicate whether the systematic review is an update11 of
a previous review, and to describe any changes in procedures from
those described in the original protocol.
Shortly after the meeting a draft of the PRISMA checklist was
circulated to the group, including those invited to the meeting but
unable to attend. A disposition ﬁlewas created containing comments
and revisions from each respondent, and the checklist was subse-
quently revised 11 times. The group approved the checklist, ﬂow
diagram, and this summary paper.
Although no direct evidence was found to support retaining or
adding some items, evidence from other domains was believed to
be relevant. For example, Item 5 asks authors to provide regis-
tration information about the systematic review, including
a registration number, if available. Although systematic review
registration is not yet widely available,12,13 the participating
journals of the International Committee of Medical Journal Editors
(ICMJE)14 now require all clinical trials to be registered in an effort
to increase transparency and accountability.15 Those aspects are
also likely to beneﬁt systematic reviewers, possibly reducing the
risk of an excessive number of reviews addressing the same
question16,17 and providing greater transparency when updating
systematic reviews.
4. The PRISMA statement
The PRISMA Statement consists of a 27-item checklist (Table 1)
and a four-phase ﬂow diagram (Fig. 1). The aim of the PRISMA
Statement is to help authors improve the reporting of systematic
reviews and meta-analyses. We have focused on randomized trials,
but PRISMA can also be used as a basis for reporting systematic
reviews of other types of research, particularly evaluations of inter-
ventions. PRISMAmayalsobeuseful for critical appraisal ofpublished
systematic reviews. However, the PRISMA checklist is not a quality
assessment instrument to gauge the quality of a systematic review.
5. From QUOROM to PRISMA
The new PRISMA checklist differs in several respects from the
QUOROM checklist, and the substantive speciﬁc changes are
highlighted in Table 2. Generally, the PRISMA checklist “decouples”
several items present in the QUOROM checklist and, where appli-
cable, several checklist items are linked to improve consistency
across the systematic review report.
The ﬂow diagram has also been modiﬁed. Before including
studies and providing reasons for excluding others, the review
Table 1
Checklist of items to include when reporting a systematic review (with or without meta-analysis).
Section/topic # Checklist item Reported on Page #
Title
Title 1 Identify the report as a systematic review, meta-analysis, or both.
Abstract
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources;
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods;
results; limitations; conclusions and implications of key ﬁndings;
systematic review registration number.
Introduction
Rationale 3 Describe the rationale for the review in the context of what is already known.
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants,
interventions, comparisons, outcomes, and study design (PICOS).
Methods
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address),
and, if available, provide registration information including registration number.
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics
(e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study
authors to identify additional studies) in the search and date last searched.
Search 8 Present full electronic search strategy for at least one database, including any limits used,
such that it could be repeated.
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review,
and, if applicable, included in the meta-analysis).
Data collection
process
10 Describe method of data extraction from reports (e.g., piloted forms, independently,
in duplicate) and any processes for obtaining and conﬁrming data from investigators.
Data items 11 List and deﬁne all variables for which data were sought (e.g., PICOS, funding sources)
and any assumptions and simpliﬁcations made.
Risk of bias in individual
studies
12 Describe methods used for assessing risk of bias of individual studies (including
speciﬁcation of whether this was done at the study or outcome level), and how
this information is to be used in any data synthesis.
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done,
including measures of consistency (e.g., I2) for each meta-analysis.
Risk of bias
across studies
15 Specify any assessment of risk of bias that may affect the cumulative evidence
(e.g., publication bias, selective reporting within studies).
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses,
meta-regression), if done, indicating which were pre-speciﬁed.
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review,
with reasons for exclusions at each stage, ideally with a ﬂow diagram.
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size,
PICOS, follow-up period) and provide the citations.
Risk of bias within studies 19 Present data on risk of bias of each study and, if available,
any outcome-level assessment (see Item 12).
Results of individual
studies
20 For all outcomes considered (beneﬁts or harms), present, for each study:
(a) simple summary data for each intervention group and
(b) effect estimates and conﬁdence intervals, ideally with a forest plot.
Synthesis of results 21 Present results of each meta-analysis done, including conﬁdence
intervals and measures of consistency.
Risk of bias across
studies
22 Present results of any assessment of risk of bias across studies (see Item 15).
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression).
Discussion
Summary of evidence 24 Summarize the main ﬁndings including the strength of evidence for each main outcome;
consider their relevance to key groups (e.g., health care providers, users, and policy makers).
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review level
(e.g., incomplete retrieval of identiﬁed research, reporting bias).
Conclusions 26 Provide a general interpretation of the results in the context of other evidence,
and implications for future research.
Funding
Funding 27 Describe sources of funding for the systematic review and other support
(e.g., supply of data); role of funders for the systematic review.
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records. Once these records have been screened and eligibility
criteria applied, a smaller number of articles will remain. The
number of included articles might be smaller (or larger) than the
number of studies, because articles may report on multiple
studies and results from a particular study may be published in
several articles. To capture this information, the PRISMA ﬂow
diagram now requests information on these phases of the review
process.6. Endorsement
The PRISMA Statement should replace the QUOROM Statement
for those journals that have endorsed QUOROM. We hope that
other journals will support PRISMA; they can do so by registering
on the PRISMAWeb site. To underscore to authors, and others, the
importance of transparent reporting of systematic reviews, we
encourage supporting journals to reference the PRISMA Statement
and include the PRISMA Web address in their Instructions to
Fig. 1. Flow of information through the different phases of a systematic review.
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endorsing PRISMA and encourage authors to adhere to its
principles.
7. The PRISMA explanation and elaboration paper
In addition to the PRISMA statement, a supporting explana-
tion and elaboration document has been produced18 following
the style used for other reporting guidelines.19e21 The process of
completing this document included developing a large database
of exemplars to highlight how best to report each checklist item,
and identifying a comprehensive evidence base to support the
inclusion of each checklist item. The explanation and elabora-
tion document was completed after several face to face meet-
ings and numerous iterations among several meeting
participants, after which it was shared with the whole group for
additional revisions and ﬁnal approval. Finally, the group
formed a dissemination subcommittee to help disseminate and
implement PRISMA.Table 2
Substantive speciﬁc changes between the QUOROM checklist and the PRISMA checklist
Section/topic Item QUOROM PRISMA Commen
Abstract O O QUOROM
PRISMA
Introduction Objective O This new
using th
interven
together
the item
Methods Protocol O This new
protocol
Methods Search O O Although
PRISMA
strategy
Methods Assessment of risk of
bias in included studies
O O Renamed
with rep
of “outco
Methods Assessment of bias
across studies
O This new
such as s
reportin
Discussion O O Although
PRISMA
of limita
Funding O This new
of fundin8. Discussion
The quality of reporting of systematic reviews is still not
optimal.22e27 In a recent review of 300 systematic reviews, few
authors reported assessing possible publication bias,22 even
though there is overwhelming evidence both for its existence28
and its impact on the results of systematic reviews.29 Even
when the possibility of publication bias is assessed, there is no
guarantee that systematic reviewers have assessed or interpreted
it appropriately.30 Although the absence of reporting such an
assessment does not necessarily indicate that it was not done,
reporting an assessment of possible publication bias is likely to be
a marker of the thoroughness of the conduct of the systematic
review.
Several approaches have been developed to conduct systematic
reviews on a broader array of questions. For example, systematic
reviews are now conducted to investigate cost-effectiveness,31
diagnostic32 or prognostic questions,33 genetic associations,34 and
policy making.35 The general concepts and topics covered by
PRISMA are all relevant to any systematic review, not just those
whose objective is to summarize the beneﬁts and harms of a health
care intervention. However, some modiﬁcations of the checklist
items or ﬂow diagramwill be necessary in particular circumstances.
For example, assessing the risk of bias is a key concept, but the
items used to assess this in a diagnostic review are likely to focus on
issues such as the spectrum of patients and the veriﬁcation of
disease status, which differ from reviews of interventions. The ﬂow
diagram will also need adjustments when reporting individual
patient data meta-analysis.36
We have developed an explanatory document18 to increase the
usefulness of PRISMA. For each checklist item, this document
contains an example of good reporting, a rationale for its inclusion,
and supporting evidence, including references, whenever possible.
We believe this document will also serve as a useful resource for
those teaching systematic review methodology. We encourage
journals to include reference to the explanatory document in their
Instructions to Authors.
Like any evidence-based endeavor, PRISMA is a living document.
To this end we invite readers to comment on the revised version,
particularly the new checklist and ﬂow diagram, through the(a tick indicates the presence of the topic in QUOROM or PRISMA).
t
and PRISMA ask authors to report an abstract. However,
is not speciﬁc about format.
item (4) addresses the explicit question the review addresses
e PICO reporting system (which describes the participants,
tions, comparisons, and outcome(s) of the systematic review),
with the speciﬁcation of the type of study design (PICOS);
is linked to Items 6, 11, and 18 of the checklist.
item (5) asks authors to report whether the review has a
and if so how it can be accessed.
reporting the search is present in both QUOROM and PRISMA checklists,
asks authors to provide a full description of at least one electronic search
(Item 8). Without such information it is impossible to repeat the authors’ search.
from “quality assessment” in QUOROM. This item (12) is linked
orting this information in the results (Item 19). The new concept
me-level” assessment has been introduced.
item (15) asks authors to describe any assessments of bias in the review,
elective reporting within the included studies. This item is linked with
g this information in the results (Item 22).
both QUOROM and PRISMA checklists address the discussion section,
devotes three items (24e26) to the discussion. In PRISMA the main types
tions are explicitly stated and their discussion required.
item (27) asks authors to provide information on any sources
g for the systematic review.
D. Moher et al. / International Journal of Surgery 8 (2010) 336e341340PRISMAWeb site. We will use such information to inform PRISMA’s
continued development.
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